Gene · 2201
FBN2: fibrillin 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. FBN2: fibrillin 2. Genes, record 2201. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2201
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P35556 | Fibrillin-2 | 2,912 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents92
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026042028 A | 2026-03-10 | 63 | P35556 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 46205 | P35556 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 46206 | P35556 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2077 | P35556 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1640 | P35556 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 5157 | P35556 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 5159 | P35556 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6348 | P35556 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6348 | P35556 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1640 | P35556 | Espacenet |
1 to 10 of 92
See all 92 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,526
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | FBN2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 7 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 6 | 2025 |
| R01AR072009 | Investigations of the molecular genetics and pathogenesis of scoliosis. | 5 | 2025 |
| P01HD084387 | Developmental Mechanisms of Human Idiopathic Scoliosis | 4 | 2025 |
| P30EY010572 | Ophthalmology Core Facility | 4 | 2025 |
| P01AI063302 | The intersection of innate and adaptive immunity to intracellular pathogens | 3 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 3 | 2025 |
1 to 10 of 1,526Source NIH's project files
See all 1,526 nih grantsPapers2,084
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sclerostin regulates bone morphogenetic protein (BMP) bioavailability through interactions with BMP complexes and fibrillin microfibrils. | FEBS J | 2026 | 42808166 | PubTator, text mining | PubMed |
| Identification and evolutionary analysis of insect fibrillin with their closely related family proteins. | PeerJ | 2026 | 42668958 | PubTator, text mining | PubMed |
| Spontaneous spinal CSF leaks: a rare variant exome sequencing study and functional analysis. | Lancet Neurol | 2026 | 42309087 | PubTator, text mining | PubMed |
| Case Report: A novel variant in fibrillin-2 identified in a congenital contractural arachnodactyly family with phenotypic heterogeneity. | Front Med (Lausanne) | 2026 | 42305963 | PubTator, text mining | PubMed |
| Two Novel FBN2 Variants Causing Congenital Contractural Arachnodactyly. | Genet Res (Camb) | 2026 | 42299845 | PubTator, text mining | PubMed |
| Cardiovascular and Clinical Manifestations of Marfan Syndrome and Other Inherited Connective Tissue Disorders with Coexisting Genetic Variants. | Cells | 2026 | 42274593 | PubTator, text mining | PubMed |
| Microfibril Denudation Marks Early Aortic Vulnerability in SMAD3 Variant Carriers: A Multigenerational Study. | Arterioscler Thromb Vasc Biol | 2026 | 42273728 | PubTator, text mining | PubMed |
| Extracellular matrix gene variants and susceptibility to sport-related musculoskeletal injuries. | J Appl Genet | 2026 | 42209954 | PubTator, text mining | PubMed |
| Genetic Polymorphisms in Systemic Lupus Erythematosus and Their Clinical Implications: A Narrative Review. | Int J Mol Sci | 2026 | 42123548 | PubTator, text mining | PubMed |
| Integrated clinicopathological, genomic, and immunophenotypic landscape of renal tubulocystic oncocytoma. | Front Immunol | 2026 | 42058215 | PubTator, text mining | PubMed |
1 to 10 of 2,084
See all 2,084 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2201
GET https://conductscience.org/api/genes/v1/2201/patents?page=2